| Identification | Back Directory | [Name]
QTX125 | [CAS]
1279698-31-5 | [Synonyms]
QTX125
QTX125,QTX-125
1H-Pyrrole-2-carboxamide, 3-(3-furanyl)-N-[[4-[(hydroxyamino)carbonyl]phenyl]methyl]-5-(4-hydroxyphenyl)- | [Molecular Formula]
C23H19N3O5 | [MDL Number]
MFCD34469284 | [MOL File]
1279698-31-5.mol | [Molecular Weight]
417.41 |
| Hazard Information | Back Directory | [Uses]
QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects[1]. | [in vivo]
QTX125 (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice[1]. | Animal Model: | Nude mice bearing REC-1 or MINO cells[1] | | Dosage: | 60 mg/kg
| | Administration: | Intraperitoneal administration; daily dosing for 5 days; for 4 weeks | | Result: | Inhibited tumor growth in REC-1 or MINO cells xenografted in nude mice. |
| [IC 50]
HDAC6 | [storage]
Store at -20°C | [References]
[1] Montserrat Pérez-Salvia, et al. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica. 2018 Nov;103(11):e537-e540. DOI:10.3324/haematol.2018.189241 |
|
|